Susan Shiff

Synthace Ltd. produces bio-based chemical and biological products through synthetic biology. It is a synthetic biology company with a platform of technologies for the rapid engineering and optimization of novel biological production systems. The bioengineering platform is broadly applicable across multiple industry sectors, including the production of specialty chemicals from renewable feed stocks using efficient and sustainable processes. The company was founded by Sean Ward and Markus Christian Gershater in January 2011 and is headquartered in, London, the United Kingdom.

Merck Global Health Innovation Fund LLC invests in companies located across the globe primarily in North America and Europe. The fund focuses on companies operating in the fields of digital health, drug discovery & clinical development, manufacturing, supply chain & it services. It provides financing for early and growth stage capital requirements with an investment size of USD 5 - 10 million.